ACCCBUZZ BLOG

ACCCBuzz recognizes June as Cancer Immunotherapy Month.

ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.

As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.

Managing immunotherapy related adverse events (irAEs) requires a team-based effort, with pharmacists playing an integral role in their identification and management within both outpatient and inpatient multidisciplinary teams.

June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.

The first post in ACCC's Subspeciality Immuno-Oncology Insights series—the APP perspective and real-world strategies for tackling current challenges in the delivery of immunotherapies for cancer.

Learn how ACCC's bispecific antibody initiative “Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management”—developed in partnership with the Society for Immunotherapy of Cancer—will help expand the use of these novel therapies and optimize care for patients with cancer.

In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.

While precision medicine in cancer care is becoming more widespread, its rapid evolution in oncology requires ongoing discussion. ACCC’s podcast, CANCER BUZZ, features lively expert discussions about emergent issues in cancer care. Here we highlight some of those podcasts.

In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.